Roper Technologies to acquire CentralReach
Leading provider of SaaS solutions for Applied Behavior Analysis therapy
SARASOTA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) today announced that it has reached a definitive agreement to acquire CentralReach from Insight Partners for a net purchase price of approximately $1.65 billion, including a $200 million tax benefit resulting from the transaction. Roper expects CentralReach to deliver sustainable 20%+ organic revenue and EBITDA growth.
CentralReach is a leading provider of cloud-native software enabling the workflow and administration of Applied Behavior Analysis ('ABA') therapy. Over 200,000 professionals utilize CentralReach's purpose-built solutions to help provide care for individuals with autism spectrum disorder ('ASD') and related intellectual and developmental disabilities ('IDD'). ABA therapy providers rely on CentralReach's comprehensive electronic medical records platform as their mission critical operating system, which includes highly specialized tools for client set-up, practice management, claims processing, care scheduling, clinical data collection, and service delivery, along with several AI-powered add-on modules.
'CentralReach is a fantastic business with clear niche market leadership, mission critical and high ROI solutions, a high recurring revenue mix, and outstanding customer retention, which leads to strong organic revenue growth and excellent cash conversion,' said Neil Hunn, Roper's President and CEO. 'This acquisition is another example of Roper identifying a business that provides greater value creation for our shareholders. CentralReach meets each of our long-standing acquisition criteria, while also having a structurally faster organic growth profile and the ability to expand margins under Roper's long-term ownership. We are excited to welcome the CentralReach team to the Roper family and look forward to partnering with the team to execute their strategy.'
Acquisition financial outlook and financing
CentralReach is expected to contribute approximately $175 million of revenue and $75 million of EBITDA for the twelve months ending June 30, 2026, and will be reported in Roper's Application Software segment. Roper expects CentralReach to deliver sustainable 20%+ organic revenue and EBITDA growth.
The transaction is expected to close in April/May 2025, subject to regulatory approval and customary closing conditions, and will be funded using Roper's revolving credit facility. Additional information about CentralReach is available in the Investors section of Roper's website (www.ropertech.com).Roper supplements its consolidated financial statements presented on a GAAP basis with certain non-GAAP financial information, including EBITDA, to provide investors with greater insight, increase transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making. Roper defines EBITDA as earnings before interest, taxes, depreciation, and amortization. Roper has not provided a reconciliation of the expected EBITDA contribution by CentralReach to the expected net income contribution by CentralReach for the twelve months ending June 30, 2026 because we are unable to quantify certain amounts that would be required to be included in CentralReach's contribution to net income without unreasonable efforts. In addition, Roper believes such reconciliation would imply a degree of precision that would be confusing or misleading to investors. The non-GAAP financial measure disclosed by Roper in this press release should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP, and the financial results prepared in accordance with GAAP and reconciliations from these results should be carefully evaluated.
About Roper Technologies
Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 1000. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market leading businesses that design and develop vertical software and technology enabled products for a variety of defensible niche markets. Roper utilizes a disciplined, analytical, and process-driven approach to redeploy its excess capital toward high-quality acquisitions. Additional information about Roper is available on the Company's website at www.ropertech.com.
About CentralReach
CentralReach is a leading provider of Autism and IDD Care Software, providing a complete, end-to-end software and services platform that helps therapists who serve children and adults diagnosed with autism spectrum disorder (ASD) and related intellectual and developmental disabilities (IDD). With its roots in Applied Behavior Analysis, the company is revolutionizing how the lifelong journey of autism and IDD care is enabled at home, school, and work with powerful and intuitive solutions purpose-built for each care setting.
Trusted by more than 200,000 professionals globally, CentralReach is committed to ongoing product advancement, market-leading industry expertise, world-class client satisfaction, and support of the autism and IDD community to propel autism and IDD care into a new era of excellence. For more information, please visit www.CentralReach.com.
Contact information: Investor Relations941-556-2601 investor-relations@ropertech.com
The information provided in this press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements may include, among others, statements regarding operating results, the success of our internal operating plans, and the prospects for newly acquired businesses to be integrated and contribute to future growth, profit and cash flow expectations. Forward-looking statements may be indicated by words or phrases such as "anticipate," "estimate," "plans," "expects," "projects," "should," "will," "believes," "intends" and similar words and phrases. These statements reflect management's current beliefs and are not guarantees of future performance. They involve risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement. Such risks and uncertainties include our ability to identify and complete acquisitions consistent with our business strategies, integrate acquisitions that have been completed, realize expected benefits and synergies from, and manage other risks associated with, acquired businesses, including obtaining any required regulatory approvals with respect thereto. We also face other general risks, including our ability to realize cost savings from our operating initiatives, general economic conditions and the conditions of the specific markets in which we operate, including risks related to labor shortages and rising interest rates, changes in foreign exchange rates, risks related to changing U.S. and foreign trade policies, including increased trade restrictions or tariffs, risks associated with our international operations, cybersecurity and data privacy risks, including litigation resulting therefrom, risks related to political instability, armed hostilities, incidents of terrorism, public health crises (such as the COVID-19 pandemic) or natural disasters, increased product liability and insurance costs, increased warranty exposure, future competition, changes in the supply of, or price for, parts and components, including as a result of inflation and potential supply chain constraints, environmental compliance costs and liabilities, risks and cost associated with litigation, potential write-offs of our substantial intangible assets, and risks associated with obtaining governmental approvals and maintaining regulatory compliance for new and existing products. Important risks may be discussed in current and subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.Sign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include: Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell Biology and Physiology, & Director of Terance Kahn Liver Research Program, Indiana University School of Medicine; and Naim Alkhouri, MD, FAASLD, DABOM, Chief Academic Officer, Summit Clinical Research, & Director of the Steatotic Liver Program, North Shore Gastroenterology, Cleveland, OH. The event will highlight results from Galectin's NAVIGATE Phase 3 clinical trial evaluating belapectin for the treatment of MASH cirrhosis and portal. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of MASH and fibrosis. With no approved therapies to prevent or treat varices in MASH cirrhosis, belapectin may represent the first potential treatment to address this significant unmet need. A live question and answer session will follow the formal presentations. About Naga P. Chalasani, MD Naga P. Chalasani, MD completed medical school in India before he moved to the US to pursue Internal Medicine residency at Emory University in Atlanta, followed by a fellowship in Gastroenterology and Hepatology at the same institution. He joined IU in 1997 as an Assistant Professor in the Division of Gastroenterology and Hepatology. Dr. Chalasani is currently David W. Crabb Professor of Gastroenterology and Hepatology and Adjunct Professor of Anatomy, Cell Biology & Physiology and as Director of Terance Kahn Liver Research Program at Indiana University School of Medicine. He previously served as the GI Division Chief (2007-2020), Associate Dean for Clinical Research (2017-2020) interim Chair of the Department of Medicine (2020-2021) and Vice President for Academic Affairs at Indiana University Health (2022-2024). He is a highly regarded clinician and ranked as Top Doctor continuously for over 15 years. He has been continuously funded by the National Institutes of Health (NIH) since 1999 and is currently the PI on several U01 and R01 awards from the NIH. Dr. Chalasani is considered an authority in the fields of Non-Alcoholic Fatty Liver Disease (NAFLD) and Drug Induced Liver Injury (DILI), two highly significant public health problems. He is one of the most published and most cited investigators at Indiana University, with Google Scholar H-Index 120 and 75,000 citations (as of Feb 2025). He is an elected member of the American Society of Clinical Investigation (ASCI), the American Association of Physicians (AAP) and the National Academy of Medical Sciences – India (2024). He has mentored over 75 undergraduate and graduate students, medical students, sub-specialty trainees, and junior faculty. Twenty of his mentees are recipients of federal funding (K award, U01, R21, R01, DOD, and VA Merit Review). To honor his contributions and mentorship, Naga P Chalasani Endowed Professor in Gastroenterology and Hepatology has been established at Indiana University School of Medicine in October 2022. About Naim Alkhouri, MD, FAASLD, DABOM Naim Alkhouri, MD, FAASLD, DABOM is the Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Program at North Shore Gastroenterology in Cleveland, OH. Prior to joining Summit, Dr. Alkhouri served as the Chief Medical Officer and Director of the Steatotic Liver Disease program at Arizona Liver Health in Phoenix, AZ. Dr. Alkhouri is a key opinion leader in the field of MASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global MASH trials and a member of the AASLD MASLD Special Interest Group (MASLD SIG). Dr. Alkhouri has been published in over 260 publications to include publications in the New England Journal of Medicine, Lancet, JAMA, Nature Medicine, Gastroenterology, Hepatology, and Journal of Hepatology. He presents his work at both national and international medical conferences. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as 'may,' 'estimate,' 'could,' 'expect', 'look forward', 'believe', 'hope' and others. They are based on management's current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin's development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not product positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company's current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin's business, see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. Company Contact:Jack Callicutt, Chief Financial Officer(678) 620-3186ir@ Investor Relations Contact:Kevin Gardnerkgardner@ Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics' galectin-3 inhibitor belapectin.
Yahoo
19 minutes ago
- Yahoo
Apple Rolls Out AI-Driven iOS 26 at WWDC
Apple (NASDAQ:AAPL) kicks off its AI and design revolution with iOS 26, unveiling a Liquid Glass interface and deeper ChatGPT integrations across core apps at WWDC 2025. Apple's vice president of Human Interface Design, Alan Dye, described iOS 26 as the broadest update ever, featuring Liquid Glassa dynamic material that marries glass-like optics with fluid responsivenessapplied universally to iPhone, iPad, Watch, TV and Mac. Native apps from Camera and Safari to Messages and Wallet get fresh layouts that adapt to context, while CarPlay and Maps gain streamlined controls. On the AI front, Apple amplifies its partnership with OpenAI by embedding ChatGPT into Image Playground and Genmoji, letting users generate bespoke images and emojis from text or photoswith full user consent. Visual Intelligence now lets you ask ChatGPT about anything on your screen without switching apps, and Live Translations delivers real-time captions and translations in Messages, FaceTime and Phoneeven with non-iPhone users. Craig Federighi, SVP of Software Engineering, announced expanded Siri personalization and an open Foundation Models Framework that enables any third-party app to tap into Apple Intelligence. Why It Matters: iOS 26's Liquid Glass aesthetic and deep AI mash-up could drive device upgrade cycles and boost services revenue as Apple rolls out paid AI features. It underscores Apple's strategy to monetize AI through its hardware moat rather than by chasing model supremacy. This article first appeared on GuruFocus.
Yahoo
23 minutes ago
- Yahoo
Intel's New Leader Tan Charts Path to Reclaim Chip Dominance
June 9 - Lip-Bu Tan took the helm at Intel (NASDAQ:INTC) this year, bringing a reputation for turnaround success from his 20092021 tenure at Cadence Design Systems (CDNS). When Tan became CEO of Cadence, its shares traded near $5.50. By the time he stepped down, the stock hovered around $186, up roughly 3,200%. That feat suggests his playbook might resonate at Intel, where shares currently trade near $20. Warning! GuruFocus has detected 7 Warning Signs with INTC. Tan has already moved to trim headcount, flatten bureaucracy and refocus on core engineering strengths. He's said Intel must shed non-core assets and sharpen its customer focus, steps likely to improve operating metrics over time. On the AI front, Tan has launched initiatives for AI-optimized hardware and software, backed by new Chief Technology and AI Officer Sachin Katti. Longer term, Intel's existing efforts in quantum computing, like its 12-qubit Tunnel Falls chip, may benefit as larger players such as Alphabet Inc. (NASDAQ:GOOG) and Inc. (NASDAQ:AMZN) seek reliable foundry partners. Intel also stands to gain from U.S. onshoring trends under the current administration. Meanwhile, the emerging humanoid robot market, projected by The Goldman Sachs Group, Inc. (GS) to reach $38 billion by 2035, could offer additional upside if Intel's processors and RealSense depth cameras become standard brains for new robotic systems. Tan's challenge is steep, but his track record suggests Intel may find a path back toward growth and greater investor confidence. This article first appeared on GuruFocus. Sign in to access your portfolio